Pfizer's bosutinib misses endpoint in Phase III trial vs Gleevec, but still "important option"
This article was originally published in Scrip
Pfizer's second-generation, investigational BCR-ABL inhibitor bosutinib has missed its primary endpoint in its first Phase III trial, BELA, pitting it against Novartis's Gleevec (imatinib) in newly diagnosed, chronic phase chronic myeloid leukaemia (CML). The study was presented at the American Society of Hematology (ASH) meeting in Orlando, Florida. The data, and the fact that Gleevec is due to come off patent in 2014, may consign the Pfizer drug to a second-line treatment for CML.